As of 2024-12-13, the Relative Valuation of GT Biopharma Inc (GTBP) is (119.26) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.80 USD, the upside of GT Biopharma Inc based on Relative Valuation is -4359.3%.
The range of the Relative Valuation is (121.60) - (135.08) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.1x - 44.9x | 34.7x |
| Forward P/E multiples | 19.8x - 31.3x | 20.5x |
| Fair Price | (121.60) - (135.08) | (119.26) |
| Upside | -4442.7% - -4924.2% | -4359.3% |
| Date | P/E |
| 2024-12-02 | -0.63 |
| 2024-11-29 | -0.65 |
| 2024-11-27 | -0.66 |
| 2024-11-26 | -0.70 |
| 2024-11-25 | -0.69 |
| 2024-11-22 | -0.71 |
| 2024-11-21 | -0.70 |
| 2024-11-20 | -0.74 |
| 2024-11-19 | -0.73 |
| 2024-11-18 | -0.68 |
| 2024-11-15 | -0.68 |
| 2024-11-14 | -0.70 |
| 2024-11-13 | -0.71 |
| 2024-11-12 | -0.71 |
| 2024-11-11 | -0.80 |
| 2024-11-08 | -0.77 |
| 2024-11-07 | -0.72 |
| 2024-11-06 | -0.69 |
| 2024-11-05 | -0.67 |
| 2024-11-04 | -0.71 |
| 2024-11-01 | -0.69 |
| 2024-10-31 | -0.68 |
| 2024-10-30 | -0.70 |
| 2024-10-29 | -0.77 |
| 2024-10-28 | -0.76 |
| 2024-10-25 | -0.72 |
| 2024-10-24 | -0.70 |
| 2024-10-23 | -0.68 |
| 2024-10-22 | -0.59 |
| 2024-10-21 | -0.56 |
| 2024-10-18 | -0.53 |
| 2024-10-17 | -0.49 |
| 2024-10-16 | -0.46 |
| 2024-10-15 | -0.46 |
| 2024-10-14 | -0.47 |
| 2024-10-11 | -0.47 |
| 2024-10-10 | -0.46 |
| 2024-10-09 | -0.48 |
| 2024-10-08 | -0.48 |
| 2024-10-07 | -0.48 |
| 2024-10-04 | -0.47 |
| 2024-10-03 | -0.49 |
| 2024-10-02 | -0.50 |
| 2024-10-01 | -0.51 |
| 2024-09-30 | -0.53 |
| 2024-09-27 | -0.49 |
| 2024-09-26 | -0.48 |
| 2024-09-25 | -0.47 |
| 2024-09-24 | -0.46 |
| 2024-09-23 | -0.46 |